Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 1997

View Archived Issues

Magnetic protein conjugates from Behringwerke

Phase I/II results reported for lobucavir in HBV

Bristol-Myers Squibb and Karo Bio to codevelop new therapies for metabolic disorders

Cell Genesys receives notice of patent claims for retroviral gene therapy vectors

Millennium reaches milestones in discovery of antibacterial drug targets

ONYX-015 combination enters phase II; U.S. patent awarded

Hirudin more effective than heparin in heart attack patients

BioTransplant and Novartis expand xenotransplantation collaboration

Mayo Clinic to collaborate in developing Dendreon's dendritic cell therapy

Safety and pharmacokinetics of new hyperlipidemia Rx in humans

Yamanouchi files for approval of hypoglycemic agent

Preliminary human evaluation of DMP-543, a potential antidementia agent

Natural compound for combatting fungal infections disclosed

Resistance modulators prepared by Byk Gulden

Schering AG presents AMPA antagonists

MS&D develops subtype-selective 5-HT1D receptor agonists for migraine

New antiarthritic agents described by Procter & Gamble

Sensus reports early clinical results with B2036-PEG

Feasibility of OROS melatonin delivery evaluated in humans

Echinocandin antifungal agent tested in patients

PRIME II: another heart failure drug associated with increased mortality

KRM-1648: a rifamycin derivative active against H. pylori and Mycobacterium spp.

Fujisawa's benzimidazole derivatives have broad therapeutic potential

Nascobal introduced in U.S., licensed to Meda for Nordic countries

New immunosuppressive, anticancer compounds from Kyowa Hakko

New agent for restenosis reported by Taiho

Lenercept evaluated in phase II for sepsis/septic shock; development for RA halted

SmithKline Beecham launches ReQuip in the U.S.

Novel squalene synthase inhibitor reported by Pfizer

Atrix seeks U.K. approval for Atridox

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...